Daiichi Sankyo extends reach in Italy, with Ranbaxy to market its products

5 October 2011

The Italian subsidiaries of Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned India-based Ranbaxy (RANB: BO) have entered into a partnership to leverage Ranbaxy’s distribution strengths and extensive relationships with pharmacists across Italy, for the distribution of Daiichi Sankyo products.

To start with, Ranbaxy will exclusively distribute two of Daiichi Sankyo’s long established brands - Congescor (bisoprolol fumarate) and Lopresor (metoprolol tartrate) - to all pharmacies, in the country. These drugs are used extensively by doctors in Italy for the treatment of congestive heart failure and hypertension, with combined retail sales of of both drugs around Euro 20 million euros ($26.8 million), according to IMS Health data quoted by the companies.

The partnership in Italy provides further impetus to the Hybrid Business Model between the two companies by comprehensively addressing doctors and pharmacists in improving the accessibility of drugs, for patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK